Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07177209

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population — Recruiting • Rheumatology • NCT07177209.

📅 27 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07177209
Sponsor
Pfizer
Start
2026-04-01
ClinicaliQ Trial Snapshot
  • Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population — Recruiting • Rheumatology • NCT07177209.
  • What is being tested: This trial characterises current treatment patterns and pathways in ulcerative colitis management, developing an updated treatment algorithm to reflect contemporary clinical practice and therapeutic sequencing.
  • Patient eligibility overview: The study includes patients with ulcerative colitis across disease severity spectrum (mild to severe), encompassing those at various stages of treatment—from newly diagnosed to those with established disease requiring escalation or switching of therapies.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Eligibility Snapshot
  • Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
  • Patient enrolled in IBD registry from 2009 2. >18 years at time of diagnosis. 3. Diagnosis of Ulcerative Colitis.
  • Patient data entered during the study period. 5. Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording,…
View guideline →
Guideline
2023 EULAR Recommendations for the Management of Gout
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility…
View guideline →
Podcast
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 00:16:21 · 03 Apr 2026
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk assessment after higher rates…
Listen →
Guideline
Osteoarthritis: Care and Management (NICE CG177)
Rheumatology · 27 Mar 2026
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before…
View guideline →
Guideline
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory…
View guideline →
Webinar
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 0.5 · 05 Apr 2026
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
Watch webinar →